2020至2022年塞内加尔东南部大规模给药对疟疾发病率的影响:一项两臂、开放标签、整群随机对照试验
在塞内加尔东南部低至中度传播地区开展两臂开放标签整群随机对照试验,60个村随机接受三周期双氢青蒿素-哌喹加单剂低剂量伯氨喹的大规模给药(MDA)或标准化疗(三周期季节性疟疾化学预防)。干预年调整后MDA效果为55%(95%CI 28至71),干预后年调整效果为26%(-17至53),未报告严重不良事件。
要点
- 干预年(2021年7-12月)调整后MDA效果为55%(95%CI 28至71)。
- 干预后年(2022年7-12月)调整后MDA效果为26%(95%CI -17至53)。
- 未报告严重不良事件。
核心结论
- 在塞内加尔东南部已扩大疟疾控制措施的低至中度传播地区,三周期双氢青蒿素-哌喹加单剂低剂量伯氨喹的MDA是安全的,并在干预年降低了疟疾负担。
- 但其持续效果较弱,可能需要继续MDA或另一项减少传播的策略。
研究设计与样本
- 研究为在塞内加尔东南部Tambacounda卫生区村庄开展的两臂、开放标签、整群随机对照试验。
- 合格村庄人口规模为200-800人,位于年疟疾发病率为每1000人60-160例的卫生站服务区内,并已建立或计划开展Prise en Charge à Domicile Plus模式。
- 2020年9月1日至10月25日,共对523个村庄进行地理定位和资格筛查,111个符合纳入标准,其中60个村庄被随机选取并分配至干预组或对照组。
- 村庄按1:1采用分层约束随机化方法分配至干预组(每6周口服双氢青蒿素-哌喹加单剂低剂量伯氨喹,共三周期)或对照组(每4周口服磺胺多辛-乙胺嘧啶加阿莫地喹进行季节性疟疾化学预防,共三周期)。
- 参与者、现场团队和所有研究者(包括结局评估和数据分析者)对分配分组均未设盲,实验室技术人员对干预分配设盲;分析采用意向性治疗原则。
主要发现
- 第一周期双氢青蒿素-哌喹全部三剂分发覆盖率为6057/8229(73.6%),第二周期为6836/8673(78.8%),第三周期为7065/8690(81.3%)。
- 第一周期单剂低剂量伯氨喹分发覆盖率为6286/7999(78.6%),第二周期为6949/8462(82.1%),第三周期为7199/8575(84.0%)。
- 第一周期季节性疟疾化学预防全部三剂分发覆盖率为3187/3457名3-120月龄儿童(92.2%),第二周期为3158/3442名(91.8%),第三周期为3139/3434名(91.4%)。
- 干预年(2021年7-12月)MDA调整后效果为55%(95%CI 28至71);干预后年(2022年7-12月)MDA调整后效果为26%(95%CI -17至53)。
- 干预后年传播季疟疾发病率在干预组为每1000人126例,对照组为每1000人146例;未报告严重不良事件。
临床怎么用
- 在塞内加尔东南部已扩大疟疾控制措施的低至中度传播地区,三周期双氢青蒿素-哌喹加单剂低剂量伯氨喹的MDA是安全的,并在干预年降低了疟疾负担。
- 作者认为其持续效果较弱,可能需要继续MDA或另一项减少传播的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin-piperaquine plus single, low-dose primaquine on Plasmodium falciparum incidence and prevalence in southeast Senegal. METHODS: We conducted a two-arm, open-label, cluster-randomised controlled trial in villages in the Tambacounda health district of southeast Senegal. Eligible villages had a population size of 200-800, were within a health-post catchment area with an annual malaria incidence of 60-160 cases per 1000 people, and had an established or planned Prise en Charge à Domicile Plus model. We randomly assigned villages (1:1) using a stratified, constrained randomisation approach to receive either three cycles of MDA with oral dihydroartemisinin-piperaquine plus single, low-dose primaquine administered at 6-week intervals (intervention) or to standard of care, which included three cycles of seasonal malaria chemoprevention (SMC) with oral sulfadoxine-pyrimethamine plus amodiaquine administered at 4-week intervals (control). Participants, the field team, and all investigators, including those who assessed outcomes and analysed data, were unmasked to allocation assignment. Laboratory technicians were masked to intervention assignment. The primary outcome was village-level, P falciparum-confirmed malaria incidence in the post-intervention year (ie, July to December, 2022). Secondary outcomes included malaria incidence during the intervention year (ie, July to December, 2021), coverage and safety of MDA, and adverse events. We conducted analyses using an intention-to-treat approach. The trial is registered with ClinicalTrials.gov (NCT04864444) and is completed. FINDINGS: Between Sept 1 and Oct 25, 2020, 523 villages were geolocated and screened for eligibility; 111 met the inclusion criteria. Of these, 60 villages were randomly selected and assigned to the intervention arm or control arm. Distribution coverage of all three doses of dihydroartemisinin-piperaquine was 6057 (73·6%) of 8229 participants in the first cycle, 6836 (78·8%) of 8673 participants in the second cycle, and 7065 (81·3%) of 8690 participants in the third cycle. Distribution coverage of single, low-dose primaquine was 6286 (78·6%) of 7999 participants in the first cycle, 6949 (82·1%) of 8462 participants in the second cycle, and 7199 (84·0%) of 8575 participants in the third cycle. Distribution coverage of all three doses of SMC was 3187 (92·2%) of 3457 children aged 3-120 months in the first cycle, 3158 (91·8%) of 3442 children aged 3-120 months in the second cycle, and 3139 (91·4%) of 3434 children aged 3-120 months in the third cycle. In the intervention year (ie, July to December, 2021), the adjusted effect of MDA was 55% (95% CI 28 to 71). In the post-intervention year (ie, July to December 2022), the adjusted MDA effect was 26% (-17 to 53). Malaria incidence during the transmission season of the post-intervention year was 126 cases per 1000 population in the intervention arm and 146 cases per 1000 population in the control arm. No serious adverse events were reported. INTERPRETATION: In southeast Senegal, a low-to-moderate transmission setting where malaria-control measures have been scaled up, three cycles of MDA with dihydroartemisinin-piperaquine plus single, low-dose primaquine was safe and reduced malaria burden during the intervention year. However, its sustained effect was weak and continuation of MDA or another transmission-reducing strategy could be required. FUNDING: US President's Malaria Initiative.
引用
- Ba EKC, Roh ME, Diallo A, et al. Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial. Lancet Infect Dis. 2025. PMID: 39799956. doi:10.1016/S1473-3099(24)00741-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。